Magenta Therapeutics (MGTA) Investor Presentation - Slideshow

MGTA-117 Targeted Conditioning - Additional clinical evidence of Proof-of-Mechanism is expected in Q4 2022[6] - Advancement into Transplant-Eligible Patients is anticipated in H1 2023[6] - MGTA-117 has the potential to reduce patient exposure to chemotherapy agents, reduce relapse, and extend survival while minimizing toxicities in blood cancer patients[14] - MGTA-117 aims to eliminate the use of busulfan in HSC gene therapy patients[15] - MGTA-117 was rapidly cleared and no longer measurable 48 hours post-dosing in Cohort 1[45] MGTA-145 Stem Cell Mobilization - Stem cell mobilization data in Sickle Cell Disease is expected in December 2022[6] - In a Phase 2 trial for Multiple Myeloma, 88% of patients achieved 2 million cells/kg, and 70% achieved 4 million cells/kg with MGTA-145[72] - In the same trial, engraftment was observed in 100% of patients (19/19)[72] CD45-ADC Targeted Conditioning - Advancement of IND-enabling studies is planned for 2023[6] - Preclinical data shows a single dose of CD45-targeted ADC depleted 90% of stem cells and 90% of immune cells in NHPs[68] Financial Status - The company projects its cash runway will extend into Q2 2024[2, 6]